Fig. 2From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adultsParticipant flow through the study (total randomised participants) *Participant presented with Hodgkin’s lymphoma and was discontinued from the study before receiving any vaccine dose †Groups 1 and 2 were further randomised to subgroups K1 (n = 40) and K2 (n = 40)Back to article page